SCHEMBL14802183

SCHEMBL14802183

CCOC(=O)C(C)(N)c1ccc(Cl)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.47
RAB9A P51151 2/20 0.44
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
MAPT P10636 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ABCB11 O95342 1/20 0.41
TSHR P16473 1/20 0.41
HTR2A P28223 1/20 0.41
PMP22 Q01453 1/20 0.41
PPARA Q07869 1/20 0.41
POLB P06746 3/20 0.41
GAA P10253 2/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17796511 0.85 DGAT1 (0.49) DGAT1RAB9ACYP1A2CYP3A4MAPT
SCHEMBL29922800 0.85 DGAT1 (0.49) DGAT1RAB9ACYP1A2CYP3A4MAPT
SCHEMBL19459161 0.84 DGAT1 (0.48) DGAT1RAB9ACYP1A2CYP3A4MAPT
SCHEMBL1508883 0.83 MAPT (0.48) RAB9ACYP1A2CYP3A4MAPTABCB11
SCHEMBL12834838 0.83 DGAT1 (0.47) DGAT1RAB9ACYP1A2CYP3A4MAPT
SCHEMBL30353376 0.81 POLB (0.51) DGAT1RAB9AMAPTPOLBGAA
SCHEMBL17410229 0.81 POLB (0.51) DGAT1RAB9AMAPTPOLBGAA
SCHEMBL2490473 0.80 CYP3A4 (0.58) CYP1A2CYP3A4MAPTCYP2C9CYP2C19
SCHEMBL31294547 0.79 DGAT1 (0.46) DGAT1RAB9ACYP1A2CYP3A4MAPT
SCHEMBL8907388 0.77 CNR2 (0.44) RAB9ACYP1A2CYP3A4MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130172362-A1 Imidazothiazole Derivatives Having Proline Ring Structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-04 US disclosed
US-20130172362-A1 Imidazothiazole Derivatives Having Proline Ring Structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-07-04 US disclosed
US-8404691-B2 Imidazothiazole derivatives having proline ring structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-03-26 US disclosed
US-8404691-B2 Imidazothiazole derivatives having proline ring structure DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172362-A1 Imidazothiazole Derivatives Having Proline Ring Structure MDM2, TP53, TP53BP1 DGAT1 3730/4885RAB9A 3726/4885CYP1A2 4028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.